AvidBiotics has received new Small Business Innovation Research (SBIR) grant from the National Institute of Allergic and Infectious Diseases of the National Institutes of Health to further develop targetable bactericidal proteins to kill Clostridium difficile bacteria.
As part of the grant, AvidBiotics will receive $600,000 funds spreading over two years.
AvidBiotics chief executive officer David Martin said Clostridium difficile has become the most frequent cause of hospital-acquired infections overtaking methicillin-resistant Staph. Aureus.
“This new funding will help support our preclinical research and advance Avidocin™ proteins towards the clinic,” Martin added.
AvidBiotics’ Avidocin antibacterial proteins will kill target organisms without collateral damage to non-targeted bacteria in bacterial health threats.
